Thryv Therapeutics Inc.

Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome

$30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors…